• Japanese
  • Korean
  • Chinese
Cover Image

Lyxumia (Type 2 Diabetes) - Forecast and Market Analysis to 2022

GlobalData has released its new report, "Lyxumia (Type 2 Diabetes) - Forecast and Market Analysis to 2022". The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Lyxumia (lixisenatide) is a fourth-to-market GLP-1 receptor agonist developed by Zealand Pharma and in-licensed to Sanofi. It was approved in the EU in February 2013, and is under review as a New Drug Application (NDA) by the FDA as of July 2013.

Scope

  • Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Lyxumia including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Lyxumia for the top ten countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Lyxumia performance
  • Obtain sales forecast for Lyxumia from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)

Table of Contents

1 Table of Contents

1 Table of Contents 5

  • 1.1 List of Tables 7
  • 1.2 List of Figures 7

2 Introduction 8

  • 2.1 Catalyst 8
  • 2.2 Related Reports 9

3 Disease Overview 12

  • 3.1 Etiology and Pathophysiology 12
    • 3.1.1 Etiology 12
    • 3.1.2 Pathophysiology 13
    • 3.1.3 Prognosis 14
    • 3.1.4 Quality of Life 15
  • 3.2 Symptoms 15

4 Disease Management 17

  • 4.1 Treatment Overview 17
    • 4.1.1 Diagnosis and Referrals 17
    • 4.1.2 Treatment Guidelines 18

5 Competitive Assessment 24

  • 5.1 Overview 24
  • 5.2 Strategic Competitor Assessment 25

6 Lyxumia (lixisenatide) 27

  • 6.1 Overview 27
  • 6.2 Efficacy 28
  • 6.3 Non-glycemic Benefits 29
  • 6.4 Safety 29

6.5 SWOT Analysis 31

  • 6.6 Forecast 31

7 Appendix 33

  • 7.1 Bibliography 33
  • 7.2 Abbreviations 36
  • 7.3 Methodology 37
  • 7.4 Forecasting Methodology 37
    • 7.4.1 Diagnosed Type 2 Patients 37
    • 7.4.2 Percent Drug-Treated Patients 38
    • 7.4.3 Drugs Included in Each Therapeutic Class 38
    • 7.4.4 Launch and Patent Expiry Dates 39
    • 7.4.5 General Pricing Assumptions 39
    • 7.4.6 Individual Drug Assumptions 40
    • 7.4.7 Generic Erosion 40
  • 7.5 Physicians and Specialists Included in this Study 41
  • 7.6 About the Authors 43
    • 7.6.1 Analyst II - CVMD 43
    • 7.6.2 Therapy Director - CVMD and Infectious Disease 43
    • 7.6.3 Global Head of Healthcare 44
  • 7.7 About GlobalData 45
  • 7.8 Disclaimer 45

List of Tables

1.1 List of Tables

  • Table 1: Symptoms of Type 2 Diabetes 16
  • Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes 17
  • Table 3: Treatment Guidelines for Type 2 Diabetes 19
  • Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012 22
  • Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012 26
  • Table 6: Product Profile - Lyxumia 28
  • Table 7: Lyxumia SWOT Analysis, 2012 31
  • Table 8: Global Sales Forecasts ($m) for Lyxumia, 2012-2022 32
  • Table 9: Key Launch Dates 39
  • Table 10: Key Patent Expiry Dates 39
  • Table 11: Number of High-Prescribing Physicians Surveyed 42

List of Figures

1.2 List of Figures

  • Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy 21
Show More
Pricing
Get Notified
Email me when related reports are published